Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction—a case series
Frontiers in Cardiovascular Medicine · 22.08.2023 · 10
DOI: 10.3389/fcvm.2023.1250185 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 22.08.2023. Verfasst von Francesco Giangiacomi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To describe the efficacy and safety of sodium-glucose cotransporter 2 inhibitors as a specific treatment for anthracycline-related cardiac dysfunction in a small real-world population.
Methods
Seven patients with anthracycline-related cardiac dysfunction were clinically and echocardiographically evaluated before and after the introduction of sodium-glucose cotransporter 2 inhibitors.
Results
After a median period of 24 weeks with uninterrupted sodium-glucose cotransporter 2 inhibitors treatment, a significant clinical improvement was observed with at least one New York Heart Association Functional Class (NHYA FC) improvement in all patients (median NYHA FC: I vs. III, p < 0.010). A noteworthy left ventricular reserve remodeling (median left ventricular end diastolic volume indexed: 53 vs. 82.5 ml/m 2 , p = 0.018; median left ventricular ejection fraction: 50% vs. 40%, p = 0.17) was also observed. Sodium-glucose cotransporter 2 inhibitors therapy was well tolerated by every patients; no cases of discontinuation or relevant side effects were observed.
Conclusion
Sodium-glucose cotransporter 2 inhibitors induce a significant clinical improvement and left ventricular reserve remodeling in patients affected by anthracycline-related cardiac dysfunction.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Dyspnea Lab, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- Cardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy.
- Haematology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Zitieren
APA
Giangiacomi, F., Faggiano, A., Cardinale, D., Rossi, F. G., Pollina, A., Gherbesi, E., Gnan, E., Carugo, S., & Vicenzi, M. (2023). Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction—a case series. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1250185
Vancouver
Giangiacomi F, Faggiano A, Cardinale D, Rossi FG, Pollina A, Gherbesi E, et al. Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction—a case series. Frontiers in Cardiovascular Medicine. 2023;10. doi:10.3389/fcvm.2023.1250185
BibTeX
@article{Giangiacomi2023,
author = {Giangiacomi, Francesco and Faggiano, Andrea and Cardinale, Daniela and Rossi, Francesca Gaia and Pollina, Alberto and Gherbesi, Elisa and Gnan, Eleonora and Carugo, Stefano and Vicenzi, Marco},
title = {Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction—a case series},
journal = {Frontiers in Cardiovascular Medicine},
year = {2023},
volume = {10},
doi = {10.3389/fcvm.2023.1250185}
}
EUVIMED